EPARs - Velcade//Bortezomib

FICHA FARMACOLÓGICA de bortezomib. Contiene la Monografía en distintos idiomas (de la Comunidad Económica Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Cerasale. ABRIL 20, 2009.-

abrir aquí:
EPARs for authorised medicinal products for human use - Velcade

Active Substance
Bortezomib
International Nonproprietary Name or Common Name
Bortezomib
Pharmaco-therapeutic Group
Antineoplastic agent
ATC Code
L01X X32

Therapeutic Indication:
VELCADE in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.

VELCADE is indicated as mono-therapy for the treatment of progressive multiple myeloma in patients who have received at least 1 prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.

Date of issue of Marketing Authorisation valid throughout the European Union
26 April 2004